SCHEDULE 13G: Third Rock Ventures Discloses Significant Stake in Rapport Therapeutics

Third Rock Ventures entities have filed a Schedule 13G, revealing beneficial ownership of 22.2% of Rapport Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Third Rock Ventures V, L.P. and its related entities (Third Rock Ventures GP V, L.P. and TRV GP V, LLC) beneficially own 7,135,233 shares of Rapport Therapeutics, Inc. common stock.
• This ownership by Third Rock Ventures V entities represents approximately 19.5% of the outstanding common stock of Rapport Therapeutics, Inc.
• Third Rock Ventures VI, L.P. and its related entities (Third Rock Ventures GP VI, L.P. and TRV GP VI, LLC) beneficially own an additional 969,218 shares of Rapport Therapeutics, Inc. common stock.
• This additional ownership by Third Rock Ventures VI entities represents approximately 2.7% of the outstanding common stock of Rapport Therapeutics, Inc.
• The combined beneficial ownership by all Third Rock Ventures entities totals 8,104,451 shares, representing approximately 22.2% of the outstanding common stock.
• The percentage of class was calculated based on 36,576,457 shares of common stock issued and outstanding as of November 6, 2024, as disclosed in Rapport Therapeutics' 10-Q filing on November 7, 2024.
• All reported shares are held with shared voting power and shared dispositive power by the respective Third Rock Ventures entities.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership without explicit positive or negative financial performance implications.

Positives

• Significant beneficial ownership by a prominent venture capital firm like Third Rock Ventures may signal confidence in Rapport Therapeutics, Inc.'s long-term prospects and strategic direction.
• The combined stake of 22.2% indicates a substantial, long-term investment by a sophisticated institutional investor.

Risks

• The filing explicitly states that Third Rock Ventures V entities and Third Rock Ventures VI entities disclaim the existence of a 'group' for purposes of Rule 13d-5 of the Securities Exchange Act of 1934, as amended, which could be a point of regulatory scrutiny if a group were deemed to exist.

Future Outlook

NA

Industry Context

Third Rock Ventures is a prominent venture capital firm specializing in life sciences, indicating a strategic investment in Rapport Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector. This type of significant institutional ownership is common for early-stage or growth-phase biotech companies, often signaling a long-term commitment from a key investor.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Company Management: Awareness of a large, concentrated ownership stake by a venture capital firm, which may imply a degree of influence or oversight.

Key Dates

Keywords

Rapport Therapeutics, Third Rock Ventures, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional ownership, biotechnology investment, venture capital